Novocure Ltd. Stock News

SHANGHAI & CAMBRIDGE, Mass. & BAAR, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology. “The data presented today from the PANOVA-3...

It's been a challenging year for NovoCure (NVCR 3.51%), an oncology-focused biotech. The stock is down by 35% since early January.

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novoc...

NovoCure's Q1 earnings beat and strong commercial momentum, especially with Optune Lua in NSCLC, signal renewed growth potential and investor optimism. Key catalysts ahead include the PANOVA-3 data at ASCO, PMA submissions, and possible NCCN guideline inclusion, all of which could drive adoption and revenue. International expansion, particularly in Europe and Japan, is accelerating, with robust...

Shares of NovoCure (NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m.

Thursday morning NovoCure (NVCR 4.28%) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.

NovoCure Limited (NASDAQ:NVCR ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Executive Chairman Ashley Cordova - CEO Christoph Brackmann - CFO Frank Leonard - EVP and President, NovoCure Oncology Nicolas Leupin - CMO Conference Call Participants Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Vijay Kumar - Evercore ...